A pharmacogenetics study of the human glucuronosyltransferase UGT1A4

Pharmacogenetics and Genomics

Volumn 19, Issue 12, 2009, Pages 945-954

  Benoit Biancamano, Marie Odile ^a   Adam, Jean Philippe ^a   Bernard, Olivier ^a   Court, Michael H ^b   Leblanc, Marie Hélène ^a   Caron, Patrick ^a   Guillemette, Chantal ^a  

^a Université Laval   (Canada)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Pharmacogenetics; Polymorphisms; Tamoxifen; UDP glucuronosyltransferase; UGT1A4

Indexed keywords

4 HYDROXYTAMOXIFEN; GLUCURONOSYLTRANSFERASE 1A4; HEPATOCYTE NUCLEAR FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 1; TAMOXIFEN;

AFRICAN AMERICAN; ARTICLE; CAUCASIAN; ENZYME ACTIVITY; EXON; GENE CONSTRUCT; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC VARIABILITY; GLUCURONIDATION; HUMAN; HUMAN CELL; INTRON; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

AFRICAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 73949095106     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283331637     Document Type: Article

References (31)

1. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 2003; 3:136-158.
2. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 2005; 15:677-685.
3. Sten T, Bichlmaier I, Kuuranne T, Leinonen A, Yli-Kauhaluoma J, Finel M. UDP-glucuronosyltransferases (UGTs) 2B7 and UGT2B17 display converse specificity in testosterone and epitestosterone glucuronidation, whereas UGT2A1 conjugates both androgens similarly. Drug Metab Dispos 2009; 37:417-423.
4. Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK, et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 2001; 11:357-368.
5. Green MD, Tephly TR. Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. Drug Metab Dispos 1996; 24:356-363.
6. Green MD, King CD, Mojarrabi B, Mackenzie PI, Tephly TR. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 1998; 26:507-512.
7. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40:581-616.
8. Court MH. Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 2005; 400:104-116.
9. Malfatti MA, Felton JS. N-glucuronidation of 2-amino-1-methyl-6- phenylimidazo (4,5-b) pyridine (PhIP) and N-hydroxy-PhIP by specific human UDP-glucuronosyltransferases. Carcinogenesis 2001; 22:1087-1093.
10. Girard H, Thibaudeau J, Court MH, Fortier LC, Villeneuve L, Caron P, et al. UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology 2005; 42:448-457.
11. Kaku T, Ogura K, Nishiyama T, Ohnuma T, Muro K, Hiratsuka A. Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 2004; 67:2093-2102.
12. Lazarus P, Blevins-Primeau AS, Zheng Y, Sun D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann N Y Acad Sci 2009; 1155:99-111.
13. Poon GK, Chui YC, McCague R, Llnning PE, Feng R, Rowlands MG, et al. Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab Dispos 1993; 21:1119-1124.
14. Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res 2006; 8:R50.
15. Ehmer U, Vogel A, Schutte JK, Krone B, Manns MP, Strassburg CP. Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 2004; 39:970-977.
16. Saeki M, Saito Y, Jinno H, Sai K, Hachisuka A, Kaniwa N, et al. Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet 2005; 20:144-151.
17. Menard V, Girard H, Harvey M, Perusse L, Guillemette C. Analysis of inherited genetic variations at the UGT1 locus in the French-Canadian population. Hum Mutat 2009; 30:677-687.
18. Wiener D, Fang JL, Dossett N, Lazarus P. Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone glucuronidation phenotype in human liver microsomes. Cancer Res 2004; 64:1190-1196.
19. Erichsen TJ, Ehmer U, Kalthoff S, Lankisch TO, Muller TM, Munzel PA, et al. Genetic variability of aryl hydrocarbon receptor (AhR)-mediated regulation of the human UDP glucuronosyltransferase (UGT) 1A4 gene. Toxicol Appl Pharmacol 2008; 230:252-260.
20. Levesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther 2007; 81:392-400.
21. Butler LM, Sinha R, Millikan RC, Martin CF, Newman B, Gammon MD, et al. Heterocyclic amines, meat intake, and association with colon cancer in a population-based study. Am J Epidemiol 2003; 157:434-445.
22. Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004; 14:501-515.
23. Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL, et al. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos 2002; 30:1257-1265.
24. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, Housman DE. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 2000; 10:629-644.
25. Villeneuve L, Girard H, Fortier LC, Gagne JF, Guillemette C. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 2003; 307:117-128.
26. Gagne JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62:608-617.
27. Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 2004; 32:775-778.
28. Verreault M, Senekeo-Effenberger K, Trottier J, Bonzo JA, Belanger J, Kaeding J, et al. The liver X-receptor alpha controls hepatic expression of the human bile acid-glucuronidating UGT1A3 enzyme in human cells and transgenic mice. Hepatology 2006; 44:368-378.
29. Mori A, Maruo Y, Iwai M, Sato H, Takeuchi Y. UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos 2005; 33:672-675.
30. Gardner-Stephen DA, Mackenzie PI. Isolation of the UDP- glucuronosyltransferase 1A3 and 1A4 proximal promoters and characterization of their dependence on the transcription factor hepatocyte nuclear factor 1alpha. Drug Metab Dispos 2007; 35:116-120.
31. Ishii Y, Hansen AJ, Mackenzie PI. Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter. Mol Pharmacol 2000; 57:940-947.